NCT06734637View on ClinicalTrials.gov

Efficacy and Safety of Peginterferon in ET and PV.

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 20, 2026

Study Completion Date

November 20, 2027

Conditions
Essential ThrombocythemiaPolycythemia Vera
Interventions
DRUG

Peginterferon α-2b injection

Participants will receive Peginterferon α-2b 180 mcg once a week and follow-up. Dose adjustments will be made by the investigator based on the type and severity of adverse event (AE).

Trial Locations (1)

Unknown

RECRUITING

Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Zhenya Hong

OTHER